Gender is an important patient characteristic that may be used to predict clinical presentation, disease progression, and therapeutic response. In recent studies, women with psoriatic arthritis (PsA) have reported less favorable function, increased fatigue, and decreased quality of life, compared to men. Less is known about gender differences with other patient-reported outcomes (PROs) such as pain and work limitations. Our purpose was to characterize gender differences in PROs in participants of the Utah Psoriasis Initiative (UPI) Arthritis Registry.
Methods:
In this cross-sectional study, PROs assessing pain, fatigue, quality of life, and function were compared between men and women enrolled in the UPI Arthritis Registry between January 2010 and November 2014. Work limitations were assessed in the subset of participants working for pay at the time of enrollment.
Results:
Participants included 115 men and 138 women. Women had less favorable PROs for pain, fatigue, patient-reported joint count, physical demands at work, work output, and function, as measured by both Health Assessment Questionnaire and the Psoriatic Arthritis Screening and Evaluation function subscale.
Conclusions:
Women experienced PsA differently than men, with higher fatigue, pain, work disability, and functional limitations. The etiology of the gender differences in PsA are unclear, and further research is indicated to better understand the role of hormones, gene expression, and other potential pathophysiologic differences between men and women.
LiuJTYehHMLiuSYChenKT. Psoriatic arthritis: epidemiology, diagnosis and treatment. World J Orthop. 2014;5(4):537–543.
2.
ZachariaeH. Prevalence of joint disease in patient with psoriasis: implication for therapy. Am J Clin Dermatol. 2003;4(7):441–447.
3.
MadlandTMApalsetEMJohannessenAERosseboBBrunJG. prevalence, disease manifestations, and treatment of psoriatic arthritis in western Norway. J Rheumatol. 2005;32(1):1918–1922.
4.
EderLThavaneswaranAChandranVGladmanDD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578–582.
5.
GeijerMLidnqvistUHusmarkT, et al.The Swedish Early Psoriatic Arthritis Registry 5-year followup: substantial radiographic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol. 2015;42(11):2110–2117.
6.
QueiroRSarasquetaCTorreJCTintureTLopez-LagunasI. Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int. 2001;21(2):66–68.
7.
NasKCapkinEDagliAZ, et al.Gender specific differences in patients with psoriatic arthritis. Mod Rheumatol. 2017;27(2):345–349.
8.
TheanderEHusmarkTAleniusGM, et al.Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favorable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407–413.
9.
GlintborgBØstergaardMDreyerL, et al.Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO Registry. Arthritis Rheum. 2011;63(2):382–390.
10.
McDonoughEAyearstREderL, et al.Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887–896.
11.
FreireMRodríguezJMollerI, et al.Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin. 2011;7(1):20–26.
12.
WuCYChangYTJuanCK, et al.Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016;95(22):e3816. doi:10.1097/MD.0000000000003816.
13.
HaddadALiSThavaneswaranACookRJChandranVGladmanDD. The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts. J Rheumatol. 2016;43(2):362–366.
14.
MeasePJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol2017;29(4):304–310.
15.
Di CarloMBeccioliniALatoV, et al.The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in the clinical setting. J Rheumatol2007;44(3):279–285.
16.
AderD. Developing the patient-reported outcomes measurement information systems (PROMIS). Medical Care Suppl2007;45(5): S1–S2.
17.
ColomboDChimentiSGrossiPA, et al.Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis. Clin Cosmet Investig Dermatol. 2015;9:1–7.
18.
Lindstrom EgholmCKroghNSPincusT, et al.Discordance of global assessments by patient and physician is higher in female than in male patients regardless of the physician’s sex: date on patients with rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis from the DANBIO registry. J Rheumatol. 2015;42(10):1781–1785.
19.
GuyattGHTownsendMBermanLBKellerJL. A comparison of Likert and visual analog scales for measuring change in function. J Chronic Dis. 1987;40(12):1129–1133.
20.
GarrettSJenkinsonTKennedyLGWhitelockHGaisfordPCalinA. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286–2291.
21.
McKennaSPDowardLCWhalleyDTennantAEmeryPVealeDJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63(2):162–169.
22.
FinlayAYKhanGK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol1994;19(3):210–216.
23.
LernerDAmickBC IIIRogersWHMalspeisSBungayKCynnD. The work limitations questionnaire. Med Care. 2001;39(1):72–85.
24.
HusniMEMeyerKHCohenDSModyEQureshiAA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581–587.
25.
FriesJFSpitzPKrainesRGHolmanHR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–145.
26.
GuduTEtchetoAde WitM, et al.Fatigue in psoriatic arthritis a cross-sectional study of 246 patients from 13 countries. Joint Bone Spine. 2016;83(4):439–443.
27.
WaleniusMSkomsvollJFKoldingsnesW, et al.Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis. 2009;68(5):685–689.
28.
QueiroRTejónPCotoP, et al.Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis. Clin Dev Immunol. 2013;2013:482691. doi:10.1155/2013/482691.
29.
ZarcoPGonzalezCMRodriguez de la SernaA, et al.Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. Reumatol Clin. 2015;11(2):83–89.
30.
HuffmeierUReisASteffensM, et al.Male restricted genetic associated of variant R620 W inPTPN22 with psoriatic arthritis. J Invest Dermatol. 2016;126(4):932–935.
31.
PongratzGStraubRHScholmerichJFleckMHarleP. Serum BAFF strongly correlates with PsA activity in male patients only—is there a role for sex hormones?Clin Exp Rheumatol. 2010;28(6):813–819.
32.
RileyJL IIIRobinsonMEWiseEAMyersCDFillingimRB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain1998;74(2-3):181–187.
33.
FillingimRBKingCDRibeiro-DasilvaMCRahim-WillimsBRileyJL III. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10(5):447–485.
34.
PicavetHSHazesJM. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003;62:644–650.
35.
WijnhovenHAde VetHCPicavetHS. Prevalence of musculoskeletal disorders is systematically higher in women than in men. Clin J Pain. 2006;22(8):717–724.
36.
MyersCDRileyJL IIIRobinsonME. Psychosocial contributions to sex-correlated differences in pain. Clin J Pain. 2003;19(4):225–232.
37.
LevineFMDe SimoneLL. The effects of experimenter gender on pain report in male and female subjects. Pain. 1991;44(1):69–72.
38.
SaadAAAshcroftDMWatsonKD, et al.Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):R52. doi:10.1186/ar2670.
39.
HeibergMSKoldingsnesWMikkelsenK, et al.The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234–240.
40.
Gomez-ReinoJJCarmonaL; BIOBADASER Group. switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29. doi:10.1186/ar1881.
41.
BrikmanSFurerVWollmanJ, et al.The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol. 2016;43(9):1749–1754.
42.
Utah Department of Health. Indicator-based information system for public health. http://ibis.health.utah.gov. Updated November 19, 2018. Access February 10, 2019.
